Pfizer to Increase Manufacturing of Paxlovid COVID-19 Treatment and Have Omicron-Specific Vaccine Ready by March

Speaking at the JP Morgan Healthcare Conference, being held virtually this year, on Monday, Pfizer CEO Albert Bourla said the company has plans to boost manufacturing of its COVID-19 treatment Paxlovid by up to 50 percent this year. Bourla said the company would achieve the scale-up by expanding its manufacturing capacity.